Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graeme Moyle

Showing results (71-80 of 120) with videos related to

Pageof 12
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2004
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patientsMarta Boffito, Laura Dickinson, Andrew Hill, et al.
HIV Medicine|February 18, 2026
The effect of Biktarvy (B/F/TAF) on whole-body insulin sensitivity, lipid and endocrine profile in healthy volunteersJoseph Heskin, Roya Movahedi, Sujin Kang, et al.
The Journal of Antimicrobial Chemotherapy|March 12, 2011
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteersAkil Jackson, Antonio D'Avolio, Victoria Watson, et al.
The Journal of Antimicrobial Chemotherapy|January 30, 2004
Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000Paul Scott, Eve Arnold, Barry Evans, et al.
AIDS Research and Human Retroviruses|August 17, 2006
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir dosesMarta Boffito, Desmond Maitland, Laura Dickinson, et al.
Vaccine|December 3, 2014
Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infectionAnna Herasimtschuk, Jocelyn Downey, Mark Nelson, et al.
The Journal of Antimicrobial Chemotherapy|December 21, 2004
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study)Chloe Orkin, Justin Stebbing, Mark Nelson, et al.
The Journal of Antimicrobial Chemotherapy|February 22, 2020
Pharmacokinetics of once-daily doravirine over 72 h following drug cessationXinzhu Wang, Ana Milinkovic, Branca Pereira, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 10, 2011
A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathyDavid B Clifford, David M Simpson, Stephen Brown, et al.
Current HIV Research|October 25, 2016
Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled TrialJoel Gallant, Graeme Moyle, Juan Berenguer, et al.
Pageof 12

Showing results (71-80 of 120) with videos related to

Sort By:
Pageof 12
Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2004
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patientsMarta Boffito, Laura Dickinson, Andrew Hill, et al.
HIV Medicine|February 18, 2026
The effect of Biktarvy (B/F/TAF) on whole-body insulin sensitivity, lipid and endocrine profile in healthy volunteersJoseph Heskin, Roya Movahedi, Sujin Kang, et al.
The Journal of Antimicrobial Chemotherapy|March 12, 2011
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteersAkil Jackson, Antonio D'Avolio, Victoria Watson, et al.
The Journal of Antimicrobial Chemotherapy|January 30, 2004
Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000Paul Scott, Eve Arnold, Barry Evans, et al.
AIDS Research and Human Retroviruses|August 17, 2006
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir dosesMarta Boffito, Desmond Maitland, Laura Dickinson, et al.
Vaccine|December 3, 2014
Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infectionAnna Herasimtschuk, Jocelyn Downey, Mark Nelson, et al.
The Journal of Antimicrobial Chemotherapy|December 21, 2004
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study)Chloe Orkin, Justin Stebbing, Mark Nelson, et al.
The Journal of Antimicrobial Chemotherapy|February 22, 2020
Pharmacokinetics of once-daily doravirine over 72 h following drug cessationXinzhu Wang, Ana Milinkovic, Branca Pereira, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 10, 2011
A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathyDavid B Clifford, David M Simpson, Stephen Brown, et al.
Current HIV Research|October 25, 2016
Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled TrialJoel Gallant, Graeme Moyle, Juan Berenguer, et al.
Pageof 12